Figure1.

RP3-326I13.1 was highly expressed in cisplatin (DDP) resistant lung adenocarcinoma (LAD) tissues and cells. (a) LncRNAs gene chip was used to detect RP3-326I13.1 expression in A549 cells and A549/DDP cells and found that RP3-326I13.1 was significantly increased in A549/DDP. (b) We found that RP3-326I13.1 was highly expressed in DDP-resistant A549/DDP cells.(c) Mann-Whitney U test shown that the expression level of RP3-326I13.1 in LAD tissues(n = 57) was significantly higher than that in adjacent tissues(n = 57).(d) Mann-Whitney U test shown that the expression level of RP3-326I13.1 in the tissues of patients with progressive LAD (cisplatin treatment-naïve) (n = 32) was significantly higher than that of patients in complete remission(n = 25). (e) Compared with A549 cells, the IC50 value of DDP enhanced in A549/DDP cells. Cytological experiments were repeated three times and their statistics were performed using t-test.*P < 0.05, **P < 0.01, ****P < 0.0001.